MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
Provided By GlobeNewswire
Last update: May 12, 2025
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
ZUG, Switzerland, May 12, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the first quarter of 2025.
Read more at globenewswire.com
